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Chronic myelogenous leukemia (CML) is a myeloproliferative disease
associated with a characteristic chromosomal translocation called
the Philadelphia chromosome. This results in the expression of the
Bcr-Abl fusion protein, a constitutively active protein tyrosine
kinase. Although there are a few treatment options with Bcr-Abl
kinase inhibitors, drug resistance is often encountered. One of the
major obstacles in overcoming drug resistance in CML is the high
endogenous levels of heat shock protein 70 (Hsp70). Resveratrol
is a phytoalexin produced by several plants. We studied the
chemotherapeutic effects and mode of action of resveratrol on
K562 (CML) cells. Resveratrol induced apoptosis in K562 cells in a
time-dependent manner. This was established by increased annexin
V binding, corroborated with an enhanced caspase-3 activity and a
rise in the sub-G0/G1 population. Resveratrol treatment also caused
suppression of Hsp70 both in mRNA and protein levels. The
downregulation of Hsp70 by resveratrol exposure was correlated
with a diminished presence of heat shock factor 1 (HSF1) in the
nucleus, and the downregulation of transcriptional activity of HSF1.
High endogenous levels of Hsp70 have been found to be a deterrent
for sensitivity to chemotherapy. We show here that resveratrol
could considerably enhance the apoptosis induction in K562 cells by
17-allylamino-17-demethoxygeldanamycin, an anticancer agent
that inhibits Hsp90 but augments Hsp70 levels. We conclude that
resveratrol significantly downregulated Hsp70 levels through
inhibition of HSF1 transcriptional activity and appreciably augmented
the pro-apoptotic effects of 17-allylamino-17-demethoxygeldanamycin.
(Cancer Sci 2008; 99: 1109–1116)
CML is characterized by the balanced reciprocal translocationbetween chromosomes 9 and 22 t (9:22) q (34:11)
giving rise to the Philadelphia chromosome.(1) As a consequence
of this translocation, a chimerical Bcr-Abl fusion protein is
expressed. This protein has constitutively active non-receptor
TK activity and plays a pivotal role in the pathogenesis of
the disease.(1) Bcr-Abl TK activity modulates a wide range of
cellular activities and signaling pathways that confer resistance
to chemotherapeutic drugs such as Ara-C and etoposide.(2,3) For
example, Bcr-Abl TK activity leads to phosphorylation and
activation of PI-3kinase,(4) p38 mitogen-activated protein
kinase,(5) and c-jun N-terminal kinase.(6) Furthermore, Bcr-Abl
regulates the activation of transcription factors like nuclear
factor κB(7) and Stat5(8) that play important roles in the genesis
of leukemia. The universal presence of Bcr-Abl fusion protein in
CML patients and its diverse range of substrates made it an
obvious target for drug development. This has led to the
development of specific small molecule kinase inhibitors against
Bcr-Abl. Imatinib mesylate (STI571) is one such TK inhibitor
of Bcr-Abl and cAbl that was approved for treatment for all
stages of the disease.(9,10) Unfortunately, resistance to imatinib
mesylate also occurs,(11–13) and an increasing number of recent
reports has documented a lack of patient response to imatinib.
This might be due to point mutations resulting in impaired
imatinib binding at the kinase activity site of Bcr-abl.(11–13)
Therefore, the search for other novel targets and new strategies
for the management of CML continues. Numerous natural
products are under investigation for their clinical efficacy in
prevention and treatment of a wide array of diseases including
cancer.(14,15) Among these, trans-resveratrol (trans-3,4′,5-tri
hydroxyl stilbenes), found in considerable amounts in grapes,
red wine, peas, nuts, and mullberries, has attracted attention due
to its many beneficial effects.(16) Different studies have established
the beneficial effects of resveratrol in cancer therapy, showing
inhibition of proliferation and induction of apoptosis in various
tumor cell lines (of different origin). Resveratrol was found to
have pro-apoptotic effects on cancer cells but displayed minimal
toxicity to human peripheral blood lymphocytes, indicating its
lack of toxicity for normal cells.(17) Efficacy of resveratrol has
been shown in rodent models of carcinogenesis.(18) Interestingly,
resveratrol also acts as a sensitizer in drug-induced apoptosis.(19)
In spite of these findings, the key molecular targets and the
precise mechanisms by which resveratrol exerts its anticancer
effect remain largely unknown.
The heat shock proteins or stress proteins Hsp70 and Hsp90
have been identified as contributors to oncogenesis, suggested
by the fact that overexpression of Hsp70 and Hsp90 leads to the
tumor-promoting potential of cells.(20) The expression of these
proteins is under the tight regulation of transcription factor
HSF1. HSF1 becomes phosphorylated due to induction by heat,
other forms of stress, or any other imbalance in cellular
homeostasis, and phopho-HSF1 trimerizes and translocates to
the nucleus to switch on the expression of Hsp70 and Hsp90.(21,22)
The cytoprotective role of the Hsps is attributed to their powerful
chaperoning activity, their ability to modulate the signal
transduction pathways, and their role in proteasome-mediated
degradation of the apoptotic and survival proteins.(22) Hsp90
inhibition is thought to be a powerful tool in cancer therapy by
virtue of its involvement in chaperoning dozens of proteins
known to be associated with oncogenesis.(23) The Hsp90 inhibitor
geldanamycin is reported to selectively sensitize Bcr-Abl-
expressing leukemia cells to cytotoxic chemotherapy.(24)
Unfortunately, Hsp90 inhibition induces Hsp70 expression
at the mRNA and protein level.(25) K562 cells also have high
endogenous levels of Hsp70. Also, anti-apoptotic effects of
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Bcr-Abl are found to be partially mediated by Hsp70 upregula-
tion.(25) Current reports also link the increased expression of Hsp70
in Ph1+ leukemia cells with imatinib resistance.(26) Even a weak
overexpression of Hsp70 is enough to make the CML cells
insensitive to treatment with imatinib as well as second generation
TK inhibitor nilotinib.(26) This is a major drawback in successfully
treating CML patients, especially those in the advanced stages
of disease. Abrogation of Hsp70 induction by small interfering
RNA has been shown to increase antileukemia activity of Hsp90
inhibitor geldanamycin.(25) However, at present the small interfering
RNA approach as a therapy can not be accomplished because
the extent of inhibition can not be modulated. Therefore, the
search for such a small molecule is warranted that would
directly compromise without completely inhibiting the chaper-
oning activities of Hsp70. In our present study we put forward
resveratrol as such a small molecule that induces apoptosis in
Ph1+ leukemia cells (K562) by targeting Hsp70, one of the chief
players involved in the pathogenesis of CML. Furthermore, we
elucidate some causative mechanisms by which resveratrol
influences the expression of Hsp70.
Materials and Methods
Materials. Resveratrol and fluorogenic caspase substrate
acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin were obtained
from Calbiochem, UK. Monoclonal mouse anti-actin and mouse
anti-Hsp70 antibodies were purchased from BD Pharmingen.
Rabbit anti-HSF1 was obtained from Abcam and secondary
antibodies were obtained from Calbiochem. pHSE-SEAP and
pTAL-SEAP vectors were from Clontech. Caspase-3 inhibitor
acetyl-asp-glu-val-asp-CHO (aldehyde) and general caspase
inhibitor Z-val-ala-asp-fluoromethylketone were purchased from
BD Pharmingen.
Cell culture and drug treatment conditions. Human chronic myeloid
(K562, KU812, and KCL 22) leukemia cells were maintained in
exponential growth in RPMI-1640 medium supplemented
with 10% heat-inactivated fetal bovine serum, 100 units/mL
penicillin and 100 µg/mL streptomycin in a humidified
atmosphere of 5% CO2 at 37°C. Resveratrol was dissolved in
dimethylsulfoxide at a concentration of 40 mM and added to
cells at the indicated concentrations.
Flow cytometric analysis. K562 cells were treated with
resveratrol (40 µM) for varying time intervals. Cells were
harvested and fixed with 70% chilled ethanol and kept at –20°C
for 24 h. These cells were washed with PBS twice and suspended
in PBS containing 20 µg RNase and kept for 2 h. These cells
were then treated with propidium iodide (100 µg/mL) and kept
in the dark for 15 min. The cell cycle of these cells was
analyzed in a Becton Dickinson flow cytometer (FACSCalibur).
Determination of caspase-3 activity. Fifty micrograms of
protein was incubated with 10 µg acetyl-Asp-Glu-Val-Asp-
aminomethylcoumarin, the fluorogenic caspase-3 substrate, in
1 mL assay buffer (20 mM HEPES [pH 7.5], 10% glycerol,
2 mM dithiothreitol) for 1 h and the reaction was stopped by
chilling. Fluorescence was measured at 380 nm excitation and
420–460 nm emission by a spectrofluorimeter.
Western blot analysis. Protein extracts (20–50 µg) were separated
by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and were transferred onto polyvinylidene difluoride membranes.
The membranes were blocked for 2 h at room temperature with
5% bovine serum albumin and incubated overnight at 4°C with
respective primary antibodies. Levels of β-actin were confirmed to
ensure equal loading of the samples. The membranes were incubated
with 1:5000 dilution of the appropriate peroxidase-conjugated
secondary antibodies and/or alkaline phosphatase-conjugated
antibodies and developed for detection by chemiluminescence
or colorimetry. Western blots were scanned by a UMAX Astra
scanner and the bands were quantified using ImageJ software.
Reverse transcription–PCR. Total RNA (2.5 µg) was reverse
transcribed with oligo(dT) primer using 0.2 mM dNTP mix, 25
U RNase inhibitor, and 100 U Moloney murine leukemia virus
reverse transcriptase. For PCR, 1 µL cDNA from the reverse
transcription reaction mixture was taken to amplify in a 25 µL
reaction volume containing 10 pmol of each primer, 200 µM
each dNTP, in buffer containing 1.5 mM MgCl2 and 5 U of Taq
polymerase. A 10 µL portion of PCR product was electrophoresed
in a 1.0% agarose gel. The following primers were used for
Hsp70 (forward, 5′-ACCCTGTCGTCCAGCACCCA3′; reverse,
5′CTGCGTCTGCTTGGTGGGGA3′) and β-Actin (forward,
5′-GAAGCA TTTGCGGTGGACCAT-3′; reverse, 5′-TCCTGTGG
CATCCACCAAACT-3′). The primer sequence of Hsp70 was
taken from the sequence of the inducible form of Hsp70
(GenBank accession number NM-005346).
Promoter assay: measurement of transcription factor-induced
gene expression. Transcription factor-induced gene regulation
was monitored by Mercury Pathway Profiling SEAP system kit
from Clontech following the manufacturer’s instructions. Cells
were transfected by corresponding plasmids as described in the
manuals. Mercury vectors are engineered in such a way that
they contain a specific cis-acting DNA binding sequence and a
sensitive reporter gene. That is, if any transcription factor binds
to the cis-acting DNA binding domain, secreatory alkaline
phosphatase will be expressed. This secreted alkaline phosphatase
was measured flurometrically by using its substrate, 4-methyl
umbeliferryl phosphate (10 µM). The transfections were induced
by calcium phosphate and the vectors pHSE-SEAP and pTAL-
SEAP were used.
Confocal microscopy. Resveratrol treated cells and control
samples were washed several times in PBS and finally suspended
in 200 µL of 1X annnexin V binding buffer containing annexin
V–fluorescein-isothiocyanate and incubated at room temperature
for 15 min in the dark. Then the samples were washed three
times and finally suspended in annexinV binding buffer. A drop
of the final suspension was mounted on a glass slide covered
with a coverslip and scanned with a confocal laser microscope
(Zeiss).
Electrophoretic mobility shift assay. Protein was collected using
the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit
(Pierce Biotechnology Inc, Rockford, IL, USA). The cytoplasmic
fraction and the nuclear fraction were subjected to Western blot
analysis for HSF1 quantification. The nuclear fraction thus
isolated was further used for electrophoretic mobility shift assay
for HSF1 and HSE binding.
Oligonucleotides bearing the sequence of the HSE (5′-GAT
CCT CGA AGG TTC GAG GAT CCT CGA AGG TTC GAG-
3′ and 5′-GAT CCT CGA ACC TTC GAG GAT CCT CGA
ACC TTC GAG-3′)(27) were end-labeled with [γ-32P] dATP by
incubating annealed oligonucleotides with 5 × reaction buffer
and 10 U T4 polynucleotide kinase (Invitrogen). Then the
labeled oligos were allowed to anneal at room temperature for
30 min. An equal amount of protein (20 µg) from each sample
was used in 25 µL binding reactions, which consisted of 1 µg
poly dI-dC, 5 × binding buffer (20 mM Tris [pH 7.5], 100 mM
NaCl, 2 mM ethylenediaminetetraacetic acid, 10% glycerol, and
10 mg/mL bovine serum albumin), and the labeled probe.
Protein lysate volumes were made to equal 5 µL by addition of
buffer (20 mM HEPES [pH 7.8], 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM ethylenediaminetetraacetic acid, and
0.5 mM phenylmethylsulphonyl fluoride). To determine specifi-
city of DNA binding, unlabeled competitor DNA was added to
the binding reactions and allowed to incubate for 10 min at
room temperature. Following this incubation, labeled probe was
added and samples were further incubated for 20 min at room
temperature. Samples were then electrophoresed on a 5% non-
denaturing polyacrylamide gel in 0.5 × TBE for 1.5 h at 120 V
and visualized by autoradiography.
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Statistical analysis. Student’s t-test was used to calculate
statistical significance of the data.
Results
Effect of resveratrol on Hsp70 protein and mRNA levels in K562
cells. We found that resveratrol downregulates the levels of
Hsp70 both at the mRNA and protein level (Fig. 1). This
downregulation was found to be dose-dependent (Fig. 1) and
time-dependent (Fig. 2). We observed the effects of 20, 40, and
100 µM resveratrol on the Hsp70 levels of K562 cells and found
that 20 µM resveratrol caused less than 20% reduction in Hsp70
protein levels, but 40 µM and 100 µM markedly reduced Hsp70
protein levels (50–80%) after a period of 48–72 h. One hundred
micromols of resveratrol caused a drastic decline of 90% in the
mRNA level of Hsp70 and a steep 80% drop in Hsp70 protein
after 48 h. As Hsp70 is also an important cellular chaperone, we
chose a dose of 40 µM resveratrol, which caused a considerable
but a less severe drop in Hsp70 levels for all further experiments.
After the initial 24 h of exposure to resveratrol, a modest drop
(approximately 20%) was observed in Hsp70 protein levels.
Resveratrol exposure for 48 h produced a significant drop
(P < 0.05) in Hsp70 protein levels (Fig. 2a) which declined
further on prolongation of incubation to 72 h (>60% decrease
from control levels; P < 0.05). Hsp70 mRNA levels declined
significantly (P < 0.01; 61% decline) on resveratrol exposure
Fig. 1. Dose–response of resveratrol-induced inhibition of heat shock protein 70 (Hsp70) levels in K562 chronic myelogenous leukemia cells.
(a) The upper panel depicts Hsp70 protein levels after treatment for 48 h with various doses of resveratrol. The lower panel shows loading control
β-actin levels. The numbers at the bottom represents Hsp70/Actin protein band densities (normalized to control). The blots are representative of
three separate experiments. (b) The upper panel depicts Hsp70 mRNA levels after treatment for 48 h with various doses of resveratrol. The lower
panel shows loading control β-actin levels. The numbers at the bottom represents Hsp70/actin mRNA band densities (normalized to control). The
blots are representative of two separate experiments. 
Fig. 2. Effect of resveratrol on heat shock
protein 70 (Hsp70) protein and mRNA levels in
K562 chronic myelogenous leukemia cells. (a)
Hsp70 protein levels. Upper panel depicts a
Western blot showing Hsp70 protein levels in
K562 cells after resveratrol exposure for 24, 48,
and 72 h. The Hsp protein is recognized by an
antibody against human Hsp70. The middle
panel shows a β-actin immunoblot to indicate
equal protein loading. The Western blots are
representative of three separate experiments.
The lower panel displays the ratio (mean ± SD)
of the Hsp70 protein/actin protein band
densities from two experiments. (b) Hsp70 mRNA
levels. Upper panel depicts mRNA levels of Hsp70
in K562 cells after resveratrol exposure for 24,
48, and 72 h. The middle panel shows β-actin
mRNA to indicate equal loading. The gels are
representative of two separate experiments. The
lower panel displays the ratio (mean ± SD) of the
Hsp70 mRNA/actin mRNA band densities from
two experiments. (c) Hsp70 protein levels in
KU812 and KCL22 human chronic myeloid
leukemia cells. Upper panel depicts Hsp70 levels
and lower panel shows β-actin levels indicatiing
equal loading. KCL, untreated KCL22 cells; KCLR,
KCL22 cells after 72 h of treatment with 40 µM
resveratrol; KU, untreated KU812 cells; KUR,
KU812 cells after 72 h of treatment with 40 µM
resveratrol. 
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for 48 h after a moderate but significant decline (P < 0.05; 39%
decrease) at 24 h, and at 72 h the decline was maintained
(drop >60%; P < 0.001). (Fig. 2b). Similarly, resveratrol
diminished Hsp70 protein levels in another CML cell line,
KCL22, with high endogenous Hsp70 levels. In contrast,
resveratrol did not have a lowering effect on already lower
levels of Hsp70 in KU812 basophilic CML cells (Fig. 2c).
Resveratrol induces apoptosis in K562 cells. First we tried to
understand whether resveratrol possessed significant apoptotic
properties on Bcr-Abl Ph1+ K562 cells. Resveratrol was found
to induce apoptosis in K562 cells in a time-dependent manner.
Cell cycle analysis with 40 µM resveratrol (Fig. 3a–d) showed
that the percentage of cells at sub-G0/G1 (fragmented DNA) rose
significantly (approximately 4–7-fold higher than the control;
P < 0.01) at 48 h of resveratrol exposure and remained similarly
high at 72 h of exposure (P < 0.05 from control). Resveratrol
exposure also caused a 2.08 ± 0.53-fold increase in caspase-3
activity (Fig. 3e) at 24 h that climbed to approximately
3.2 ± 0.73-fold by 48 h and further to 4.31 ± 0.01-fold by 72 h
(P < 0.05). The increase in caspase activity was not responsible
for the decrease in Hsp70 levels. As Fig. 3f shows, the caspase-3
inhibitor and general caspase inhibitor failed to block the decline
in Hsp70 levels brought about by resveratrol. During apoptosis,
PS translocates from the cytoplasmic face of the plasma
membrane to the cell surface. Annexin V has a strong, Ca2+-
dependent affinity for PS and therefore is used as a probe for
detecting apoptosis. K562 cells treated with resveratrol showed
a considerable translocation (Fig. 3g) of PS to the cell surface
over the control untreated cells, as detected by confocal imaging.
Resveratrol prevents HSF1 transcriptional activity and nuclear
localization of HSF1. Hsp70 synthesis is controlled by the
transcription factor HSF1 which binds to the HSE controlling
Hsp70 gene expression.(21) As resveratrol inhibits Hsp70 at the
mRNA level, we next investigated if resveratrol has any critical
impact on HSF1. To explore the mechanism underlying the
reduction of Hsp70, we measured the levels of cytoplasmic and
nuclear HSF1 by Western blot analysis (Fig. 4a,b). It was found
that resveratrol promoted (Fig. 4a) a considerable augmentation
(approximately 7-fold) of HSF1 in the cytoplasmic fraction at
36 h of treatment in a time-dependent manner. In contrast,
resveratrol prominently decreased the levels of nuclear HSF1
(Fig. 4b). In accordance with this finding, it was also found that
resveratrol clearly decreased (approximately 50%) binding of
HSF1 from the nuclear extracts of K562 cells to the HSE DNA
Fig. 3. Apoptosis induced by 40 µM resveratrol
in K562 chronic myelogenous leukemia cells. (a–
c) Cell cycle analysis of K562 cells by flow
cytometry. (a) Cell cycle analysis of control (0 h)
K562 cells, cells treated with resveratrol for 48 h
(b), and cells treated with resveratrol for 72 h (c).
M1, sub-G0/G1; M2, G1; M3, S; M4, G2 phase of
the cell cycle. (d) Percentage of cells in sub-G0/G1
(fragmented DNA), as determined by flow
cytometry, after 0 h, 48 h, and 72 h of resveratrol
treatment. Data are presented as mean ± SD
from two or three separate experiments. (e)
Caspase-3 activity after K562 cells were exposed
to resveratrol, presented as the fold increase
over control levels (mean ± SD) from two
separate experiments. (f) Western blot analysis
of heat shock protein 70 (Hsp70). Upper panel,
Hsp70; lower panel, β-actin indicating equal
loading. K-ctl, untreated K562 cells; K+C3I+R,
K562 cells pretreated for 1 h with caspase-3
inhibitor and further treated with both inhibitor
and 40 µM resveratrol for 72 h; K+PCI+R, K562
cells pretreated for 1 h with general caspase
inhibitor and further treated with both inhibitor
and 40 µM resveratrol for 72 h; K+R, K562 cells
treated for 72 h with 40 µM resveratrol. (g)
Confocal micrographs of annexin V binding to
K562 cells after exposure to resveratrol for 72 h.
1, Control annexinV–fluorescein-isothiocyanate
(FITC); 2, differential interference contrast of the
same field as 1; 3, 72 h resveratrol treated
annexinV–FITC; 4, differential interference
contrast of the same field as 3. 
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sequence (Fig. 4c). The promoter assay for HSE (Fig. 4d)
indicated that HSF transcriptional activity is significantly
inhibited by resveratrol (P < 0.01).
Resveratrol and Hsp90 inhibitor 17-AAG mutually potentiate their
anti-apoptotic effects in K562 cells. Fig. 5 shows that resveratrol
in combination with moderate concentrations of 1, 2.5, and
5 µM 17-AAG induced apoptosis in K562 cells. Fig. 5b–d
shows that 17-AAG alone at concentrations of 1–5 µM caused a
moderate amount of apoptosis, as indicated by the presence
of a significantly (P < 0.01) higher percentage of cells in
sub-G0/G1. Fig. 5f–h shows that, in combination with resveratrol,
17-AAG treatment promoted a higher amount of DNA
fragmentation (P < 0.01 for 1 µM and P < 0.05 for 2.5 and
5 µM 17-AAG; Fig. 5i). 17-AAG treatment, along with
resveratrol, also enhanced the apoptotic effect of resveratrol in
K562 cells (P < 0.01). Fig. 6a–c shows the effect of 17-AAG
treatment on Hsp70 levels of K562 cells. Hsp70 protein
and mRNA levels were brought down by concomitant use of
resveratrol and 17-AAG when compared with cells treated
only with 17-AAG (Fig. 6a–c). Hsp70 mRNA levels were
noticeably reduced by resveratrol and 1 µM 17-AAG
combination (Fig. 6a and 33% drop from control levels) and
Hsp70 protein levels were also similarly reduced from control
levels (41 ± 1.4% decline; data not shown). However, there was
no boost in Hsp70 mRNA levels (Fig. 6a) and only a slight
increase in Hsp70 protein levels by 1 µM 17-AAG treatment
alone (18 ± 8.5% increase; data not shown). In contrast, on
addition of 2.5 µM 17-AAG alone, the Hsp70 protein and
mRNA levels (Fig. 6b,c) were markedly increased (2-fold and
3-fold, respectively). When resveratrol was combined with
2.5 µM 17-AAG, both Hsp70 mRNA and protein levels
diminished from the 17-AAG-induced enhanced levels (Fig. 6b,c).
However, the drop in mRNA and protein levels of Hsp70 caused
by the combined treatment of 17-AAG (2.5 µM) and resveratrol
was not sufficient enough to bring the values below control
levels.
Fig. 4. Heat shock factor 1 (HSF1) cellular
localization, HSF1 binding to heat shock element
(HSE), and HSE promoter activity in K562 chronic
myelogenous leukemia cells after treatment
with resveratrol. (a) Upper left panel, cytoplasmic
localization of HSF1 at different time points
after resveratrol treatment. Lower left panel, β-
actin immunoblot to indicate protein loading.
Right-hand panel, cytoplasmic HSF1 band densities
of control and resveratrol treated K562 cells
expressed as percentage of control. Control has
been taken as 100%. The blot is representative
of two separate experiments. (b) Upper left
panel, nuclear localization of HSF1 at different
time points after resveratrol treatment. Lower
left panel, histone 2B immunoblot to indicate
equal protein loading. Right-hand panel, nuclear
HSF1 band densities of control and resveratrol
treated K562 cells expressed as percentage of
control. Control has been taken as 100%. The blot
is representative of two separate experiments.
(c) Left panel, electrophoretic mobility shift
assay. Arrow indicates HSF1–HSE binding. 12,
nuclear extract of K562 cells treated with
resveratrol for 12 h; 24, nuclear extract of K562
cells treated with resveratrol for 24 h; 36,
nuclear extract of K562 cells treated with
resveratrol for 36 h; BL, blank without nuclear
extract; C, control. Right-hand panel, HSF1–HSE
binding band densities of control and K562
cells treated with resveratrol for 36 h (R36).
Representative of two separate experiments.
(d) HSE promoter activity. Data are presented as
mean ± SD of percentage of control HSE promoter
activity from two or three experiments. The
secreted alkaline phosphatase assay fluorescence
value for untreated control K562 cells were taken
as 100%. Details of the experimental procedure
are given in the Materials and Methods section.
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Effect of resveratrol on non-adherent WBC from normal human
blood. Non-adherent WBC were collected from normal
volunteers after obtaining informed consent. The Hsp70 protein
levels in these cells were found to be extremely low in
comparison with K562 cells (Fig. 7, upper panel). Furthermore,
the levels of sub-G0/G1 fragmented DNA observed in these cells
with or without exposure to resveratrol were similar (Fig. 7,
lower panel) indicating that resveratrol (40 µM) exposure for
48 h did not cause any change in apoptosis of normal non-
adherent WBC. This is in agreement with previous findings by
Clement et al.(17) that resveratrol shows minimal toxicity in
normal peripheral blood lymphocytes.
Discussion
Resveratrol is a phytoalexin with potent chemopreventive and
chemotherapeutic properties against a wide array of diseases.(28)
In this study we tried to establish the pro-apoptotic role of
resveratrol in CML cells and to elucidate the mechanisms
underlying this action. Although there are reports of induction
of apoptosis by resveratrol in other forms of leukemia and
cancer models,(29) its effects on the promotion of apoptosis in
CML have not been extensively studied. Our results show that
resveratrol can induce apoptosis in K562 cells in a time-
dependent manner. This apoptosis induction involves PS
externalization, the activation of caspase-3, and increased
percentage of cell population with fragmented DNA (sub-G0/G1)(Fig. 3). All these data put together confirm the ability of
resveratrol to induce apoptosis in K562 cells.
The anti-apoptotic chaperone Hsp70 is found to be highly
expressed in K562 cells and it may present a major challenge in
inducing apoptosis in K562 cells. An important role for Hsp70
has been described, in its inhibition of apoptosis in acute leuke-
mia and in imatinib resistance in CML.(26)Thus, the challenge to
induce apoptosis in K562 cells is to overcome the highly over-
expressed levels of Hsp70.
We found that resveratrol possesses the property of downreg-
ulating Hsp70 levels both at the mRNA and protein levels
(Fig. 1) in K562 cells. This downregulation was found to be
time and dose dependent in nature. As Hsp70 is a chaperone and
is required for providing a cytoprotective role in stress condi-
tions, the complete abrogation of Hsp70 might be lethal to nor-
mal cells. Our results suggest that a concentration of 40 µM
resveratrol was sufficient in inducing apoptosis in K562 cells
without completely abrogating the Hsp70 status. Therefore,
inhibition of Hsp70 levels with resveratrol provides a good
compromise between maintenance of normal chaperone activity
and induction of apoptosis.
As the two main chaperones, Hsp70 and Hsp90, are associ-
ated with the anti-apoptotic property of cells, they also play a
crucial role in promoting tumorigenesis and imparting greater
survival of cancerous cells under cytotoxic stress.(30) STA-4783,
a novel small molecule drug candidate, induces a rapid and sig-
nificant oxidative stress response, leading to apoptosis in many
human cancer cells.(31) As a protective response to substantial
oxidative stress, the expression of Hsps, metallothioneins, and
antioxidant genes are enhanced by STA-4783. But this protec-
tive response fails because the sustained production of reactive
oxygen species overpowers the protective response and drives
the cells to apoptotic death.(31) Therefore, in all likelihood, the
heat shock response induced by STA-4783 is a minor effect
completely overwhelmed by the major effect of the drug, which
is sustained production of reactive oxygen species in the cancer
cells. Hence, the anticancer effect of STA-4783 might not
involve the increase in heat shock proteins. Much of the focus
of targeted therapy for cancer has been the designing of Hsp90
inhibitors, namely geldanamycin, 17-AAG, and spheredin.(32)
But the efficacy of these drugs is rendered low as they do not
inhibit Hsp70, and inhibition of Hsp90 might lead to HSF1-
mediated higher expression of Hsp70.(25) 17-AAG is known to
decrease Bcr-Abl levels,(33) and Bcr-Abl is associated with
increased expression of Hsp70.(25) However, 17-AAG is also
known to induce Hsp70 expression.(25) In this study, 1 µM 17-
AAG did not appreciably increase Hsp70 levels, but a combina-
tion of 17-AAG (1 µM) and resveratrol decreased Hsp70 levels
(30–40% decrease from control levels). In contrast, 2.5 µM 17-
AAG augmented both protein and mRNA levels of Hsp70
(Fig. 6b,c) in agreement with previous reports.(25) This was
brought down by combining 17-AAG (2.5 µM) with resveratrol,
but to levels still higher than those of the control. In our study,
17-AAG alone did not diminish Hsp70 levels, rather, 17-AAG
treatment resulted in a noticeable increase in Hsp70 levels. The
addition of resveratrol with 17-AAG significantly increased
the apoptotic effects of 17-AAG and diminished Hsp70 levels.
Therefore, the increase in DNA fragmentation observed by the
simultaneous application of resveratrol and 17-AAG over treat-
ment by 17-AAG alone could be connected to the status of
Hsp70. In essence, resveratrol treatment along with 17-AAG
produced a higher amount of apoptosis in K562 cells compared
to 17-AAG alone as the former abrogated the levels of Hsp70,
Fig. 5. Combined activity of anticancer drug 17-allylamino-17-demethoxygeldanamycin (17-AAG) and resveratrol in K562 chronic myelogenous
leukemia cells. (a–d) Cell cycle analysis by flow cytometry of control and 17-AAG treated K562 cells. (a) Control untreated K562 cells; (b) 1 µM 17-
AAG; (c) 2.5 µM 17-AAG; (d) 5 µM 17-AAG. (e–h) Cell cycle analysis by flow cytometry of K562 cells treated for 48 h with 40 µM resveratrol only
(e) and with both resveratrol (40 µM) and 17-AAG at concentrations of 1 µM (f), 2.5 µM (g), or 5 µM (h). M1, sub-G0/G1; M2, G1; M3, S; M4, G2
phase of the cell cycle. (i) Percentage of sub-G0/G1 cells in K562 cells treated with 17-AAG and resveratrol. Data are presented as the mean ± SD
of three or four separate experiments. The cells were subjected to the treatments detailed above for a period of 48 h. 
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whereas Hsp90 was inhibited by 17-AAG. As described in
recent published reports,(25,33) 17-AAG could have two entirely
opposite effects on Hsp70. 17-AAG, through its lowering effect
on Bcr-Abl,(33) might bring down Hsp70 levels as Bcr-Abl is
known to enhance the expression of Hsp70.(25) In total contrast,
17-AAG-induced inhibition of Hsp90 can trigger Hsp70
increase by enhancing the availability of HSF1 required for
Hsp70 transcription.(25) In the present study it seems likely that
17-AAG treatment of K562 cells might have followed the sec-
ond possibility. Hsp90 from normal cells bind 17-AAG with a
100-fold lower affinity than Hsp90 derived from cancer cells.(34)
This high affinity of cancer cell-derived Hsp 90 is explained by
the presence of activated Hsp90 complexes in cancer cells. Also,
Hsp90 client proteins in normal cells are less sensitive to 17-AAG
than similar proteins expressed in cancer cells.(35) Therefore,
cytotoxicity of 17-AAG to normal cells is not foreseen.
Once the inhibitory effects of resveratrol on Hsp70 levels
were confirmed, the need to uncover the underlying mechanisms
became urgent. Resveratrol clearly blocked translocation of
HSF1 to the nucleus, resulting in a predominantly cytoplasmic
localization of HSF1 (Fig. 4). As HSF1 requires phosphorylation
at specific amino acid residues for it to trimerize and translocate
to the nucleus, and subsequently to act as the active transcription
factor for the Hsp70 gene, resveratrol might block this phospho-
rylation by interacting with the kinases involved in the process.
The efficacy of resveratrol as a chemopreventive and sensitizer
for anticancer drug therapy has been stressed by many recent
studies.(19,36) Apart from directly targeting Hsp70, resveratrol
could exert its pro-apoptotic effects through downregulation of
inhibitors of apoptosis like survivin. The downregulation of
inhibitors of apoptosis may be direct or through inhibition of the
chaperone function of Hsp70. Recently, the option of using natural
products in the treatment of hematological malignancies received
encouragement when a report came out that the tea polyphenol
epigallocatechin gallate could produce favorable responses in
Fig. 6. Heat shock protein 70 (Hsp70) status of K562 chronic
myelogenous leukemia cells treated with 17-allylamino-17-
demethoxygeldanamycin (17-AAG) and resveratrol. (a) Upper panel,
Hsp70 mRNA levels in K562 cells treated with 1 µM 17-AAG and 40 µM
resveratrol; lower panel, β-actin levels in K562 cells treated with 1 µM
17-AAG and 40 µM resveratrol. C, control; C+Res, K562 cells treated
with resveratrol; AAG1, 1 µM 17-AAG; AAG1+Res, resveratrol and 1 µM
17-AAG. Ratio of Hsp70/β-actin mRNA (normalized to control) is
presented as the mean of data from two separate experiments. (b)
Upper panel, Hsp70 protein levels in K562 cells treated with 2.5 µM 17-
AAG and 40 µM resveratrol; lower panel, β-actin levels in cells treated
with 2.5 µM 17-AAG and 40 µM resveratrol. C, control; AAG2.5, 2.5 µM
17-AAG; AAG2.5+Res, resveratrol and 2.5 µM 17-AAG. Ratio of Hsp70/
β-actin protein (normalized to control) is presented at the bottom. The
scan is representative of two separate experiments. (c) Upper panel,
Hsp70 mRNA levels in 2.5 µM 17-AAG and 40 µM resveratrol treated
K562 cells; lower panel, β-actin mRNA levels in 2.5 µM 17-AAG and
40 µM resveratrol treated K562 cells. C, control; AAG 2.5, 2.5 µM 17-
AAG; AAG2.5+Res, resveratrol and 2.5 µM 17-AAG. Ratio of Hsp70/β-
actin mRNA (normalized to control) is presented at the bottom. The
cells were subjected to the treatments mentioned above for a period of
48 h. The scan is representative of two separate experiments. 
Fig. 7. Status of heat shock protein 70 (Hsp70) levels in normal non-
adherent white blood cells (WBC) and the effect of resveratrol on sub-
G0/G1 DNA in these cells. (a) Western blot of Hsp70 protein in K562
chronic myelogenous leukemia cells and normal non-adherent WBC.
Upper panel, Hsp 70 protein levels; lower panel, β-actin levels. (b,c) Cell
cycle analysis by flow cytometry of normal non-adherent WBC with (c)
or without (b) 40 µM resveratrol exposure. M1, sub-G0/G1; M2, G1; M3,
S; M4, G2 phase of the cell cycle.
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chronic lymphoid leukemia and follicular lymphoma.(37) For the
first time we report that resveratrol could downregulate the high
endogenous Hsp70 levels in K562 cells. Recent studies have
shown(26) that the anti-apoptotic effects of Bcr-Abl in leukemia
are partially mediated by increased expression of Hsp70. So
identification of natural compounds that could downregulate
Hsp70 can provide an option for sensitizing cancerous cells to
conventional drugs and radiation therapy. Therefore, resveratrol
might offer an option for adjunct therapy alongside inhibitors of
Bcr-Abl and Hsp90. Our study also established that resveratrol
downregulated Hsp70 through inhibition of HSF1 transcrip-
tional activity, mediated by a blockage of nuclear translocation
of HSF1.
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